BeOne Medicines Ltd (6160) Gets a Buy from Nomura
Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts
Chinese biotech overtakes AI as emerging-market growth trade
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment